The startup specializes in particle engineering technology that processes drugs without solvents or heat by depositing fine, cohesive secondary materials to create tailored composite microparticles. This method provides businesses with cost-effective and environmentally friendly manufacturing capabilities, ensuring reliable just-in-time production.
Funding
$2.2M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
DVFounders
Product
Problem
Many pharmaceutical manufacturing processes rely on traditional methods that use heat, solvents, or mechanical mixing, which can degrade sensitive active pharmaceutical ingredients (APIs), increase production costs, and pose environmental concerns. Existing powder-blending techniques often struggle to achieve uniform distribution of APIs, especially at low concentrations, leading to inconsistent dosage forms.
Solution
Aston Particle Technologies provides a novel particle-engineering solution based on its patented Isothermal Dry Particle Coating (iDPC) technology. iDPC is a solvent-free, low-shear process that coats fine particles onto larger carrier particles without heat or mechanical mixing. This one-step process uses a rotating chamber and inert gas to fluidize and disperse powders, enabling precise control over particle layering and API concentrations, ranging from <0.1% to 90% w/w. The iDPC process enhances API stability, improves dissolution rates, and ensures consistent dosage delivery across various pharmaceutical applications. The technology is scalable from benchtop R&D to pilot-scale manufacturing, facilitating a seamless transition from formulation development to commercial production.
Target Audience
The primary customers are pharmaceutical and biotechnology companies seeking advanced formulation solutions for small molecule and biological APIs, including those developing respiratory, biological, and oral dosage forms.
Features
- Patented iDPC technology for solvent-free, low-shear particle coating
- Precise control over API concentration, from <0.1% to 90% w/w
- Scalable process from benchtop (1-20g) to pilot scale (up to 2kg) and semi-continuous manufacturing (10 kg/h)
- Suitable for processing both small molecule and biologic APIs
- Enables formulation of double and triple combination products
- Enhances dissolution rates of poorly soluble APIs
- Can tailor API release profiles for immediate or delayed release
- Uses GRAS (Generally Recognized As Safe) excipients
- Quality by Design (QbD) risk-based approach using only three critical process parameters